Drug profile · INN
mogamulizumab
POTELIGEO
mogamulizumab (POTELIGEO) is a c-c chemokine receptor type 4 cross-linking agent. Associated with KYOWA KIRIN AUSTRALIA PTY LTD.
EMA: approved TGA: approved PMDA: approved Antineoplastic and immunomodulating agents (L01) L01XC25
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — mogamulizumab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
mogamulizumab (POTELIGEO) is a c-c chemokine receptor type 4 cross-linking agent. Associated with KYOWA KIRIN AUSTRALIA PTY LTD.
Key facts
INN mogamulizumab
Brand POTELIGEO
Mechanism C-C chemokine receptor type 4 cross-linking agent
Target C-C chemokine receptor type 4
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XC25
Originator KYOWA KIRIN AUSTRALIA PTY LTD
Mechanism of action
C-C chemokine receptor type 4 cross-linking agent
Primary target: C-C chemokine receptor type 4
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mogamulizumab?
mogamulizumab (POTELIGEO) is a c-c chemokine receptor type 4 cross-linking agent. Associated with KYOWA KIRIN AUSTRALIA PTY LTD.
What is the brand name for mogamulizumab?
POTELIGEO is a marketed brand name for mogamulizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.